Bart Cobert

Bart Cobert

bcobert@gmail.com

Pharmacovigilance, Drug Safety and Regulatory Affairs Author & Expert

Bart is a pharmacovigilance and drug safety consultant with 30 years in the pharmaceutical industry. He was a founding member and working group chair in ICH, and has written 4 textbooks on drug safety. Bart offers expertise in all areas of strategic pharmacovigilance including data management committees, mock Advisory Committee meetings, FDA & EMA/MHRA/AFSSAPS interactions, compliance, training, risk management (REMS/RMPs), crisis management, medical & safety analyses & white papers, and organizational change management. He is also a board certified gastroenterologist.

Does Rapid FDA Approval Produce Drug Safety Issues?

/ Mar 16, 2020

Bart Cobert gives his pharmacovigilance point of view on a recent paper on FDA approval timelines and drug safety issues.

Read More

Clintrials.gov Update

/ Feb 11, 2020

Bart Cobert on the importance of publishing clinical trials data and implications on pharmacovigilance.

Read More

Pharmacovigilance 2030

/ Dec 11, 2019

This is an interesting article looking at what PV will be in the year 2030.

Read More

FDA Draft Guidance on PMRs

/ Nov 24, 2019

Bart Cobert highlights the most important changes in the recently revised FDA draft guidance on PMRs.

Read More

Ranitidine – What Happened and What Do We Learn?

/ Oct 31, 2019

Bart Cobert explores several important points to take from the still ongoing signal and safety issue with Renitidine recall.

Read More

Vaping – A Serious Safety Signal

/ Oct 07, 2019

Bart Cobert discusses the major safety issue in the US on e-cigarettes and vaping.

Read More

Importing Canadian Drugs to the US

/ Aug 29, 2019

Bart Cobert covers several issues involved in setting up the proposed "Safe Importation Plan" which aims to allow US consumers to get safe and cheaper drugs.

Read More

No-No’s in Drug Safety

/ Aug 13, 2019

An overview covering a number of things to avoid doing when it comes to drug safety.

Read More

Different Regulatory Actions from Different Agencies

/ Jun 27, 2019

Bart Cobert explores the potential reasons for the differing regulatory actions from the different agencies.

Read More

Reporting and Not Reporting Data

/ Jun 03, 2019

Bart Cobert discusses the importance of clinical safety reporting. Not only is this a legal responsibility but also an ethical one.

Read More